If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide injection): Common Adverse Reactions
In clinical studies, the most common adverse reactions, or side effects, associated with Forteo treatment were nausea, joint aches, and pain.
Overview
In clinical studies, the most common adverse reactions associated with teriparatide treatment were nausea, joint aches, and pain.
In addition, common side effects observed with teriparatide treatment included
- muscle spasms (leg spasms, back spasms), and
- injection site reactions (redness, swelling, pain, itching, a few drops of blood, bruising).1
Serious Adverse Events
Orthostatic Hypotension With Teriparatide Therapy
Teriparatide may cause transient orthostatic hypotension.1
Typically in clinical studies, transient orthostatic hypotension began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When an event occurred, it happened within the first several doses and was relieved by placing patients in a reclining position.1
Teriparatide should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.1
Serum Calcium Elevation With Teriparatide Therapy
Teriparatide may cause slight and transient increases in serum calcium. Maximum concentrations are observed at approximately 4 and 6 hours postdose and returns to baseline at least 16 to 24 hours postdose.1
Therefore, if blood samples for serum calcium are taken, it should be done at least 16 hours after the most recent teriparatide injection.1
Enclosed Prescribing Information
Reference
1Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.
Date of Last Review: February 23, 2020